Expanded access treatment for ligamentous laxity
Part of Eyes & vision clinical trials.
This trial provides access to a treatment for people with ligamentous laxity caused by a rare enzyme problem called plasminogen deficiency. The aim is to offer the treatment to a small group while gathering more information.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of ligamentous laxity linked to Type I plasminogen deficiency.
- You must be willing to sign a consent form agreeing to the treatment and data use.
- You must be available for the treatment period and follow-up visits.
- You must agree to tell your study doctor about any issues that come up during treatment.
- If you are of childbearing age, you must not be pregnant or plan to become pregnant, and you must agree to use birth control.
- If you are nursing, you cannot join this trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies donated blood-plasma samples as a treatment for ligneous conjunctivitis caused by Type 1 plasminogen deficiency. It may help reduce or improve the eye inflammation and growths linked to this specific genetic problem.
This trial tests a special laser treatment called Direct Selective Laser Trabeculoplasty (DSLT) for people with pseudoexfoliation glaucoma, a type of glaucoma that can be harder to treat. The treatment aims to lower eye pressure and may help delay or avoid the need for daily eye drops.
This trial tests a gene therapy called LX107 for people with vision loss caused by changes in the AIPL1 gene. It aims to see if the treatment is safe and can improve vision.
This trial tests an injection (PUMCH-E111) for people with a specific genetic form of inherited retinal dystrophy caused by RLBP1 mutations. It aims to see if the treatment is safe and can help preserve vision.
This study looks at people diagnosed with type 1 plasminogen deficiency (a condition with low plasminogen levels) and can also include their first-degree family members. It may help researchers learn more about the condition and how to monitor it over time by collecting blood and genetic information.
This trial tests a laser treatment to prevent a type of glaucoma called angle closure. It is for people who have a narrow drainage angle in the eye but do not yet have glaucoma or other serious eye conditions.
Hear when a new Ligneous Conjunctivitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.